Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Both pemetrexed and cetuximab have single agent activity in NSCLC and non-overlapping
toxicity profiles. While 2-drug combination therapy has proven superior to single agent
therapy in the first-line setting of NSCLC, no such phase III trials have been reported in
the second-line setting. Therefore, the purpose of this study is to determine the feasibility
of combining these drugs, assessing the toxicity profile, determining the MTD and evaluating
the activity of the combination in an expanded phase II setting. If the combination appears
to have promising activity, further evaluation of this regimen may be warranted comparing it
to single agent pemetrexed or cetuximab alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nasser Hanna, M.D.
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC Walther Cancer Institute